company background image
0HKD logo

Axogen LSE:0HKD Stock Report

Last Price

US$18.17

Market Cap

US$672.0m

7D

16.7%

1Y

128.5%

Updated

10 Jan, 2025

Data

Company Financials +

My Notes

Capture your thoughts, links and company narrative

Axogen, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Axogen
Historical stock prices
Current Share PriceUS$18.17
52 Week HighUS$17.20
52 Week LowUS$5.57
Beta1.01
1 Month Change22.18%
3 Month Change22.41%
1 Year Change128.49%
3 Year Change102.87%
5 Year Changen/a
Change since IPO-36.15%

Recent News & Updates

Recent updates

Shareholder Returns

0HKDGB Medical EquipmentGB Market
7D16.7%1.4%0.3%
1Y128.5%-8.0%6.6%

Return vs Industry: 0HKD exceeded the UK Medical Equipment industry which returned -8% over the past year.

Return vs Market: 0HKD exceeded the UK Market which returned 6.6% over the past year.

Price Volatility

Is 0HKD's price volatile compared to industry and market?
0HKD volatility
0HKD Average Weekly Movement9.9%
Medical Equipment Industry Average Movement6.5%
Market Average Movement4.7%
10% most volatile stocks in GB Market10.7%
10% least volatile stocks in GB Market2.6%

Stable Share Price: 0HKD's share price has been volatile over the past 3 months compared to the UK market.

Volatility Over Time: 0HKD's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of UK stocks.

About the Company

FoundedEmployeesCEOWebsite
n/a427n/awww.axogeninc.com

Axogen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin.

Axogen, Inc. Fundamentals Summary

How do Axogen's earnings and revenue compare to its market cap?
0HKD fundamental statistics
Market capUS$672.01m
Earnings (TTM)-US$14.31m
Revenue (TTM)US$180.86m

3.7x

P/S Ratio

-47.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0HKD income statement (TTM)
RevenueUS$180.86m
Cost of RevenueUS$38.43m
Gross ProfitUS$142.43m
Other ExpensesUS$156.74m
Earnings-US$14.31m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

Mar 04, 2025

Earnings per share (EPS)-0.33
Gross Margin78.75%
Net Profit Margin-7.91%
Debt/Equity Ratio50.0%

How did 0HKD perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/10 19:25
End of Day Share Price 2025/01/10 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Axogen, Inc. is covered by 17 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Michael GormanBTIG
Caitlin CroninCanaccord Genuity
William PlovanicCanaccord Genuity